Abstract 4546
Background
Half of all patients with esophageal cancer present with advanced disease at diagnosis. The most optimal treatment for this group has not been identified yet. Therefore, we evaluated a weekly regimen of carboplatin for 6 cycles (area under the curve (AUC) of 4) + paclitaxel 100mg/m2 as induction (iCT) or palliative treatment (pCT).
Methods
All patients with advanced (gastro-) esophageal cancer treated with this regimen between 2002-2018 at the Erasmus MC Rotterdam were included. Patients who received radiotherapy or were treated elsewhere were excluded. Data on toxicity, response, and survival were collected from patient records. Analyses were performed in 2 groups: iCT or pCT. Median progression free survival (PFS) and median overall survival (OS) were estimated with the Kaplan-Meier method.
Results
A total of 291 patients was included (iCT:122; pCT:169). Most patients had T3 carcinoma (iCT:54%; pCT:66%), and stage IV disease (iCT:42%; pCT:91%). The majority of the tumors were adenocarcinomas (iCT:50%; pCT:70%) and located at the distal esophagus (iCT:47%; pCT:73%). Incidence of severe grade ≥3 gastrointestinal toxicity was low (iCT:3%; pCT:5%). Grade ≥3 toxicity occurred mainly as hematological toxicity (iCT:71%; pCT:73%) with grade ≥3 neutropenia of 43% and grade 4 of 25% in both groups. Nonetheless, only 3% of patients experienced febrile neutropenia. Premature termination of the planned cycles due to toxicity occurred in 12% of the iCT group and 17% of the pCT group. Cycle delay due to toxicity occurred in 42% (iCT) and 43% (pCT) of the patients. Sensory neuropathy was low-graded and seen in 25% (iCT) and 26% (pCT) of the patients. Overall response rates were 48% (iCT) and 44% (pCT). Esophagectomy or definitive chemoradiotherapy followed in 42% of iCT, resulting in a PFS of 22.1 months (interquartile range (IQR): 12.4-114.2) and OS of 26.8 months (IQR: 15.4-91.7). For pCT, PFS was 8.2 months (IQR: 5.1-14.5) and OS 10.9 months (IQR: 6.5-18.3).
Conclusions
Weekly carboplatin (AUC4) and paclitaxel (100mg/m2) as an outpatient regimen is well-tolerated and an effective induction or palliative treatment regimen for patients with locally advanced or metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.H.J. Mathijssen.
Funding
Has not received any funding.
Disclosure
R.H.J. Mathijssen: Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Cristal Therapeutics; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pamgene; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi; Honoraria (institution): Servier; Honoraria (institution): Novartis; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract